Full-Time

Project Engineer 2

Posted on 11/23/2025

Integer Holdings Corporation

Integer Holdings Corporation

1,001-5,000 employees

Medical device CDMO for cardiac devices

No salary listed

Kilkenny, Ireland

In Person

Category
Process Engineering
Requirements
  • Bachelor's degree in any engineering or related technical field
  • Master's degree in engineering or related technical field is preferred but not required
  • Candidates who do not meet the education requirement may be considered with 10+ years of relevant experience
  • Strong Project Management experience; PMP certification is preferred but not required
  • Clear and professional communications skills and ability to communicate to all levels of the organization
  • Ability to work independently as well as collaboratively with cross functional teams
  • Ability to manage multiple projects (2-3) from start to finish and lead project meetings
  • Experience with scope and requirements gathering, risks, project planning, issues log, and stakeholder management
  • Experience creating Bills of Materials, procurement, and managing budgets versus forecast
  • Ability to develop and maintain project documents and provide project status updates to senior management
  • Experience reviewing procedures and plans prior to implementation, and evaluating existing products, processes and materials for failure analysis and improvements
  • Ability to collaborate with quality, manufacturing, design, controls, maintenance and other functions to ensure project delivery on time, scope, and budget
  • Experience initiating and maintaining relationships with individuals and business units and ability to influence others to achieve goals
  • Ability to apply standard data analysis practices to establish root cause for product and process failures or support improvements
  • Ability to observe products and processes to identify discrepancies and determine root cause
  • You will embed quality within the engineering discipline and adhere to the Quality Management System and support quality KPIs
  • Ability to participate in projects that investigate, develop, document, and implement new product and process technologies of moderate complexity and scope
  • Ability to follow Integer’s standard quality management and production system methodologies
  • You will perform other duties as needed and as directed by supervision
Responsibilities
  • Lead 2-3 projects related to Manufacturing, Equipment build, Site Capacity expansion, or Engineering from start to finish
  • Run weekly project meetings and provide project status updates to senior management
  • Maintain project documents and manage scope, requirements, risks, and issues
  • Create Bills of Materials, coordinate procurement, and manage budgets vs forecast
  • Coordinate with cross-functional teams including quality, manufacturing, design, controls, and maintenance to ensure project delivery on time, within scope and budget
  • Initiate and maintain relationships with individuals and business units within the site or organization
  • Demonstrate proactive insight into technical challenges and mitigate potential issues or implement improvements
  • Review procedures and plans prior to implementation and evaluate existing products, processes, and materials for failure analysis and improvements
  • Participate in projects that investigate, develop, document, and implement new product and process technologies of moderate complexity and scope
  • Apply standard data analysis to establish root cause for product and process failures or support improvements
  • Observe products and processes to identify discrepancies and determine root cause
  • Collaborate with others to exchange information and check for understanding to support engineering development
  • Embed Quality within the Engineering discipline and adhere to Quality Management System, support corrective and preventive actions, and contribute to quality KPIs
  • Perform other duties as needed and directed by supervision
Desired Qualifications
  • PMP certification preferred but not required
  • Master's degree in Engineering or related field preferred
  • Strong communication and facilitation skills in manufacturing environment
  • Willingness to work independently and cross functional teams
  • Experience with quality systems and manufacturing processes in medical device or regulated environment
  • Experience with root cause analysis and corrective actions (CAPA)
  • Experience leading cross-functional project teams
  • Experience with Bill of Materials management and procurement processes
  • Experience with site capacity expansion projects
  • Knowledge of regulatory requirements for medical devices (FDA QSR, ISO 13485)
Integer Holdings Corporation

Integer Holdings Corporation

View

Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

1940

Simplify Jobs

Simplify's Take

What believers are saying

  • Board initiated strategic review on April 30, 2026, exploring sale options.
  • Irenic Capital acquired $99M stake in Q4 2025 as top holding.
  • $200M share repurchase authorization signals management confidence in valuation.

What critics are saying

  • Class action lawsuits by Pomerantz and Bleichmar drain cash via settlements by Q4 2026.
  • Three new products cause 3-4% headwind, slashing H2 2026 margins.
  • Irenic activism forces sale at depressed valuation below $93 target in 12 months.

What makes Integer Holdings Corporation unique

  • Integer specializes in contract manufacturing for Cardio & Vascular medical devices.
  • Organic revenue grew 1.3% in Q1 2026 despite flat overall sales.
  • Robust pipeline targets above-market growth by 200 basis points in 2027.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Adoption Assistance

Parental Leave

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 24th, 2026
Integer VP sells $70K in shares as stock drops 28% in a year

Integer Holdings Corporation shares fell 28% following an insider sale disclosure. Tom Thomas, the company's vice president and corporate controller, sold 825 shares of common stock in an open-market transaction on 13 March 2026, according to an SEC Form 4 filing. The transaction was valued at $70,000 at a reported price of $85 per share. The sale represented 15.85% of Thomas's direct holdings at the time. Following the transaction, Thomas holds 4,380 shares worth approximately $364,000. This marks Thomas's third open-market sale since 2018, following previous sales of 884 shares in November and 1,500 shares in April. Integer Holdings manufactures medical devices and components, generating $1.85 billion in trailing twelve-month revenue.

Yahoo Finance
Feb 26th, 2026
Integer Holdings Q4 earnings beat forecasts on strong Cardio & Vascular demand

Integer Holdings, a medical device manufacturer, reported fourth quarter revenue of $472.1 million and adjusted earnings per share of $1.76, both exceeding analyst expectations. The company posted 5% year-on-year revenue growth, driven by strong performance in its Cardio & Vascular segment. CEO Peyman Khales attributed $30 million in operational improvements to higher sales volume, manufacturing efficiencies and expense management. The company guided adjusted earnings per share of $6.54 for 2026, beating analyst estimates by 3.8%. During the earnings call, analysts questioned the narrowing of organic sales guidance, first quarter margin compression and the company's path to above-market growth in 2027. Management emphasised collaborative customer planning and reaffirmed its current strategy despite activist investor involvement.

Intellectia.AI
Feb 23rd, 2026
Irenic Capital takes $99M stake in Integer Holdings as medical device firm posts 8% sales growth

Irenic Capital Management has acquired a $99.11 million stake in Integer Holdings, purchasing 1,263,663 shares in Q4 2026. The position represents 13.7% of Irenic's assets under management, making it the fund's largest disclosed equity holding. Integer Holdings, a medical device company, achieved 8% sales growth in 2025, reaching $1.85 billion in revenue, with adjusted earnings per share rising 21% to $6.40. The company reported fourth-quarter sales of $472 million and net income of $62 million, up 22% year-over-year. Management projects 2026 adjusted earnings per share between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027. Benchmark analyst Robert Wasserman upgraded the stock from hold to buy with a $95 price target.

Yahoo Finance
Feb 23rd, 2026
Integer posts 21% adjusted EPS growth but warns of H1 2026 headwinds from slower product adoption

Integer Holdings reported strong 2025 results with sales up 8% and adjusted earnings per share rising 21% to $6.40, alongside margin expansion and $105 million in free cash flow. The company returned capital through a $50 million share repurchase and announced an additional $50 million accelerated share repurchase programme. However, management warned that three newer products representing approximately 6% of 2025 sales are experiencing slower-than-expected adoption, creating a 3%–4% headwind for 2026. The company expects flat-to-slightly-down sales and a 200–250 basis point hit to first-quarter operating margin, with recovery and margin expansion anticipated in the second half. Integer maintained its 2026 midpoint guidance, with year-end net debt expected at $1.17–1.19 billion and net leverage remaining at 3.0 times adjusted EBITDA.

Yahoo Finance
Feb 19th, 2026
Integer faces 2026 headwinds from delayed product launches despite $200M buyback and robust pipeline

Integer Holdings, a medical device contract manufacturing organisation, reported fourth-quarter sales of $472 million, up 5% year-over-year, with adjusted earnings per share at the high end of its October guidance range. For the full year 2025, sales increased 8% on a reported basis and over 6% organically, whilst adjusted operating income rose 13%. The company issued 2026 guidance expecting reported sales to be down 1% to up 1%, with a 3% to 4% headwind from three new products facing lower-than-expected market adoption. However, Integer's underlying business is expected to grow 4% to 6%, in line with the market. Integer repurchased $50 million of shares in Q4 and announced plans for an additional $50 million accelerated share repurchase programme under its $200 million authorisation.

INACTIVE